Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

AUTOR(ES)

Peggs, K S

FONTE

Blackwell Science Inc

RESUMO

The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use.

Documentos Relacionados

• High expression of co-stimulatory and adhesion molecules are observed on eosinophils during human Schistosoma mansoni infection
• AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes.
• Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
• Cancer immunotherapy: avoiding the road to perdition
• Mycobacterial Phosphatidylinositol Mannosides Negatively Regulate Host Toll-like Receptor 4, MyD88-dependent Proinflammatory Cytokines, and TRIF-dependent Co-stimulatory Molecule Expression*